Duration of Treatment for Acinetobacter baumannii Pneumonia

General Recommendations

The American Thoracic Society recommends that for ventilator-associated pneumonia caused by gram-negative non-fermenting bacteria, including Acinetobacter spp., treatment should be maintained for at least 14 days to reduce the risk of recurrence 3
The Intensive Care Medicine guidelines suggest that the duration of antimicrobial therapy for Acinetobacter baumannii infections should be based on the location and severity of the infection, with a minimum of 14 days for severe infections such as ventilator-associated pneumonia or sepsis 1, 2
For severe Acinetobacter baumannii pneumonia, the treatment should be initiated with 14 days of appropriate antimicrobial therapy, and the clinical response should be evaluated at days 3-5, with consideration of adjunctive therapy with nebulized antibiotics if the response is inadequate 1, 2, 3

The American Thoracic Society documented a significant trend towards higher recurrence rates when the treatment duration was less than 14 days in patients with ventilator-associated pneumonia caused by gram-negative non-fermenting bacteria, including Acinetobacter spp. 3
A study demonstrated that patients with ventilator-associated pneumonia caused by gram-negative non-fermenting bacteria, including Acinetobacter, had higher recurrence rates with short courses of antibiotics 1

For severe Acinetobacter baumannii pneumonia, the treatment should be maintained for 14 days without exception, especially in patients with sepsis or septic shock 1, 2
For less severe infections, shorter durations (7-10 days) may be considered only if there is no hemodynamic compromise and a rapid clinical response is observed 1, 2

Avoiding short courses (≤7 days) in Acinetobacter baumannii pneumonia is recommended, as this bacterium persists in the respiratory tract despite in vitro susceptibility 3
Extending treatment unnecessarily beyond 14 days is not recommended, as it only leads to colonization with antibiotic-resistant bacteria without additional clinical benefit 3

For patients who do not respond to systemic therapy or when the MIC of colistin is near the susceptibility breakpoint, adjunctive nebulized colistin (2-6 million IU daily in 2-3 divided doses) should be considered 1, 2
Nebulized antibiotics may increase cure rates, especially when using a vibrating plate nebulizer 1, 2